Genmab — Maj 2024
-
ASCO er noget atypisk for Genmab's kursudvikling i år..... I hvert fald de seneste år, har aktien i hvert fald steget pænt op imod ASCO, for efterfølgende at blive ramt af de ledeste tømmermænd i form af kursfald..... Tør vi håbe på at det bliver lige omvendt i år?.... For mit vedkommende er det en ren gyser
-
Børsen gentager verdens 10 bedst sælgende lægemidler. 3. Ozempic 14 mia. USD, 10. Darzalex 9,7 mia. USD https://borsen.dk/nyheder/virksomheder/se-listen-novo-storsaellert-blandt-de-bedst-saelgende-i-verden?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
Med hensyn til spørgsmålene i går om Hexa38, så er bedste kilde indtil videre vist nok statig artiklen fra the Lancet: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00228-1/fulltext
-
"
We’re advancing our DuoBody
platform technology with the goal to unlock the potential of #bispecific antibody research, as we work to transform how cancer is treated. Watch the video below to learn more about our technology. #ASCO24" https://x.com/Genmab/status/1796542979273809922?t=SBZtpWL3ba-xUGouEiqH3Q&s=19 -
-
Enhanced CDC: Hexabody-CD38 is engineered to enhance complement-dependent cytotoxicity (CDC) through hexamerization. This increased CDC activity can overcome the reduced sensitivity to complement-mediated lysis seen in DARA-resistant patients due to the upregulation of complement inhibitory proteins (CD55 and CD59).
-
Broader Mechanisms: Hexabody-CD38 not only enhances CDC but also maintains other mechanisms of action such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis induction. These multiple mechanisms provide a robust anti-tumor activity, which is beneficial for overcoming resistance
-
No Inhibition by Preincubation with DARA: Preclinical studies indicate that preincubation with DARA does not inhibit Hexabody-CD38 from reaching its full capacity to induce CDC, suggesting that Hexabody-CD38 can still be effective even if DARA has been used previously.
-
In Vivo and Ex Vivo Efficacy: Hexabody-CD38 has demonstrated strong anti-tumor activity in patient-derived xenograft (PDX) models and primary MM cells, including those from DARA-refractory patients, indicating its potential effectiveness in a clinical setting.
-
In summary, the combination of enhanced CDC, robust multi-faceted mechanisms of action, effectiveness in lower CD38 expression levels, and promising preclinical results all suggest that Hexabody-CD38 should help patients who are resistant to Darzalex. The ongoing clinical trials will provide further validation of its safety and efficacy in this patient population.
-
ASCO LBA out: Subcutaneous amivantamab vs intravenous amivantamab https://meetings.asco.org/abstracts-presentations/232405 . seems like a slam dunk.
ja ja ved godt det nok ikke holder i virkeligheden. men her er hvad Chat GPT 4.0 siger om emnet i bullet points
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind